Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia CorpfiledCriticalPharmacia Corp
Priority claimed from NZ513962Aexternal-prioritypatent/NZ513962A/en
Publication of NZ533700ApublicationCriticalpatent/NZ533700A/en
Disclosed is a composition comprising and a process for preparing a solvated crystalline form of eplerenone, wherein: the solvated crystalline form can be desolvated to yield Form L crystalline eplerenone characterised by an X-ray powder diffraction pattern at a wavelength of 1.54056 angstroms, and the solvated crystalline form is selected from methyl ethyl ketone, 1-propanol, 2-pentanone, acetic acid, acetone, butyl acetate, chloroform, isobutanol, ethanol, isobutyl acetate, methyl acetate, ethyl propionate, n-butanol, n-octanol, isopropanol, propyl acetate, propylene glycol, t-butanol, tetrahydrofuran, toluene, methanol, and t-butyl acetate solvates. The disclosed process is useful in the preparation of a pharmaceutical composition for the treatment or prevention of an aldosterone-mediated condition.
NZ533700A1999-12-082000-12-04Eplerenone crystalline form
NZ533700A
(en)
Transition metal complexes in organic synthesis. Part 68: Iron-mediated total synthesis of mukonine and mukonidine by oxidative cyclization with air as the oxidizing agent
Inhibitors of sterol synthesis. A highly efficient and specific side-chain oxidation of 3 beta-acetoxy-5 alpha-cholest-8 (14)-en-15-one for construction of metabolites and analogs of the 15-ketosterol.